Boston Trust Walden Corp Has $19.04 Million Holdings in InMode Ltd. $INMD

Boston Trust Walden Corp decreased its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 3.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,318,853 shares of the healthcare company’s stock after selling 46,438 shares during the period. Boston Trust Walden Corp’s holdings in InMode were worth $19,044,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Inspire Investing LLC acquired a new position in InMode during the second quarter worth $185,000. KLP Kapitalforvaltning AS boosted its holdings in InMode by 14.1% during the second quarter. KLP Kapitalforvaltning AS now owns 50,900 shares of the healthcare company’s stock worth $735,000 after purchasing an additional 6,300 shares during the last quarter. Taylor Frigon Capital Management LLC boosted its holdings in InMode by 6.0% during the second quarter. Taylor Frigon Capital Management LLC now owns 97,496 shares of the healthcare company’s stock worth $1,408,000 after purchasing an additional 5,562 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in InMode by 302.3% during the second quarter. Farther Finance Advisors LLC now owns 8,110 shares of the healthcare company’s stock worth $117,000 after purchasing an additional 6,094 shares during the last quarter. Finally, Parallel Advisors LLC boosted its holdings in InMode by 63.1% during the second quarter. Parallel Advisors LLC now owns 1,973 shares of the healthcare company’s stock worth $28,000 after purchasing an additional 763 shares during the last quarter. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Trading Up 0.9%

NASDAQ INMD opened at $15.44 on Wednesday. The firm has a market capitalization of $975.95 million, a P/E ratio of 6.25 and a beta of 2.09. The firm’s fifty day moving average price is $14.82 and its two-hundred day moving average price is $14.71. InMode Ltd. has a 1 year low of $13.14 and a 1 year high of $19.85.

InMode (NASDAQ:INMD) last posted its earnings results on Wednesday, July 30th. The healthcare company reported $0.47 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.03). The company had revenue of $95.60 million for the quarter, compared to analyst estimates of $98.45 million. InMode had a return on equity of 18.38% and a net margin of 44.50%.The business’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.34 EPS. On average, research analysts anticipate that InMode Ltd. will post 1.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on INMD. Zacks Research upgraded shares of InMode from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Barclays dropped their price target on shares of InMode from $24.00 to $21.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 30th. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research report on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of InMode in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group upped their price target on shares of InMode from $14.00 to $16.00 and gave the stock a “hold” rating in a research report on Friday, October 10th. One investment analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $18.21.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.